Menlo Therapeutics announced that the FDA has granted breakthrough therapy designation for serlopitant for the treatment of pruritus associated with prurigo nodularis, or PN. Menlo is currently enrolling patients in two Phase 3 clinical trials to evaluate serlopitant as a treatment for pruritus associated with prurigo nodularis. Data from each trial is expected by Q1 of 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.